All In Biotech

NDA 202107 · Corcept Therap

Korlym

Mifepristone · Oral · Progestin Antagonist

Orphan

Last checked: Nov 20, 2026Latest source record: Nov 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Feb 17, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

184

37 Phase 3, 8 recruiting

FAERS reports

4,775

2,955 serious, 352 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with KORLYM and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential. WARNING: TERMINATION OF PREGNANCY See full prescribing information for complete boxed warning. Mifepristone has potent antiprogestational effects and will result in the termination of...

What it is approved for

From the label in effect Sep 25, 2025.

KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important Limitations of Use: Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.

Mechanism: Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KORLYM · MIFEPRISTONE 300MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mifepristone" as an intervention, any sponsor and status, largest first.

All 184 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea805
  • fatigue700
  • blood potassium decreased457
  • vomiting442
  • dizziness408
  • headache392
  • haemorrhage361
  • blood pressure increased350
  • abortion incomplete335
  • blood glucose increased321
  • asthenia286
  • blood glucose decreased285

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200451
20055
200618
200724
200836
20093
201072
20111
201295
2013241
2014406
2015332
2016201
2017344
2018409
2019298
2020379
2021297
2022351
2023274
2024245
2025364
2026329

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Korlym (Mifepristone)

2024 spending

$342M

Beneficiaries

1,700

10,079 claims

Per beneficiary

$201,039

$691.93 per unit

View as table
YearSpending
2020$153,690,299
2021$165,795,595
2022$187,312,598
2023$228,814,734
2024$341,766,725

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 759 on PubMed

Sponsor: Corcept Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.